ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200 Day Moving Average – What’s Next?

ImmuCell Corporation (NASDAQ:ICCC) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.12 and traded as high as $6.72. ImmuCell shares last traded at $6.56, with a volume of 10,233 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

ImmuCell Stock Performance

The company has a quick ratio of 1.76, a current ratio of 4.21 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $59.37 million, a P/E ratio of 25.23 and a beta of 0.18. The business has a fifty day moving average price of $5.78 and a 200-day moving average price of $6.12.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) EPS for the quarter. The business had revenue of $5.51 million during the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC raised its stake in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the period. Geode Capital Management LLC owned about 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. 13.47% of the stock is owned by hedge funds and other institutional investors.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.